Correspondence 0001213900-23-070101 from Scinai Immunotherapeutics Ltd. (SCNI)
Scinai Immunotherapeutics Ltd.
Date: Aug. 23, 2023 · CIK: 0001611747 · Accession: 0001213900-23-070101
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-274078
Letter
BiondVax Pharmaceuticals Ltd.
Jerusalem BioPark, 2nd Floor
Kiryat Hadassah, Building 1, JBP
Jerusalem, Israel 9112001
August 23, 2023
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Ms. Cindy Polynice
Re: REQUEST FOR ACCELERATION OF EFFECTIVENESS
BiondVax Pharmaceuticals Ltd. (CIK No. 0001611747)
Registration Statement on Form F-3 (File No. 333-274078)
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, BiondVax Pharmaceuticals Ltd. (the “Company”) hereby requests acceleration of the effective date of its Registration Statement on Form F-3 (File No. 333-274078) so that it will be declared effective at 10:00 a.m., Eastern Standard Time, on August 25, 2023, or as soon thereafter as is practicable.
Should you have any questions regarding this letter, please do not hesitate to contact Perry Wildes, Adv., at +972 (3) 607-4444 or perry@gkh-law.com, of Goldfarb Gross Seligman & Co., counsel to the Company.
Sincerely,
BIONDVAX PHARMACEUTICALS LTD.
Show Raw Text
CORRESP
1
filename1.htm
BiondVax
Pharmaceuticals Ltd.
Jerusalem BioPark, 2nd Floor
Kiryat Hadassah, Building 1, JBP
Jerusalem, Israel 9112001
August 23, 2023
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Ms. Cindy Polynice
Re: REQUEST FOR ACCELERATION OF EFFECTIVENESS
BiondVax Pharmaceuticals Ltd. (CIK No. 0001611747)
Registration Statement on Form F-3 (File No. 333-274078)
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of
1933, as amended, BiondVax Pharmaceuticals Ltd. (the “Company”) hereby requests acceleration of the effective date of its
Registration Statement on Form F-3 (File No. 333-274078) so that it will be declared effective at 10:00 a.m., Eastern Standard Time, on
August 25, 2023, or as soon thereafter as is practicable.
Should you have any questions regarding this letter,
please do not hesitate to contact Perry Wildes, Adv., at +972 (3) 607-4444 or perry@gkh-law.com, of Goldfarb Gross Seligman & Co.,
counsel to the Company.
Sincerely,
BIONDVAX PHARMACEUTICALS LTD.
By:
/s/ Amir Reichman
Amir Reichman
Chief Executive Officer